Updates are available Correction dated 2024-08-13

Article History

Received: 30 December 2023

Revised: 1 May 2024

Accepted: 7 May 2024

First Online: 9 July 2024

Change Date: 13 August 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41440-024-01835-z

Compliance with ethical standards

:

: GFM is owner of Cardiovascular Engineering, Inc., a company that designs and manufactures devices that measure vascular stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. GFM also serves as a consultant to and receives grants and honoraria from Novartis, Merck, Bayer, Servier, Philips, and deCODE genetics and is an inventor on a pending patent application that discloses a method for estimating carotid-femoral pulse wave velocity and vascular age by using a convolutional neural network. The remaining authors declare that they have no competing interests.